Accessibility Menu
Ono Pharmaceutical logo

Ono Pharmaceutical(OTC) OPHLF

Current Price$14.61
Market Cap$6.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-50%
5 Year-24%
1 Year+38%
1 Month+8%
Ono Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 14.612026-07-24
Ono Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.11%USD 14.452026-07-17
1 month+8.22%USD 13.502026-06-22
3 month+2.18%USD 14.302026-03-30
Year to date+15.52%USD 12.652025-12-23
1 year+37.53%USD 10.622025-07-24
3 year-9.98%USD 16.232023-07-24
5 year-23.82%USD 19.182021-07-23
Since inception-50.26%USD 29.382003-07-08

Ono Pharmaceutical Financials at a Glance

Market Cap

$6.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥518.51B

Net Income (TTM)

¥70.20B

EPS (TTM)

$0.99

P/E Ratio

14.70

Dividend

$0.52

Beta (Volatility)

0.09 (Low)

Price

$14.61

Volume

1,011

Open

$15.33

Previous Close

$14.61

Daily Range

$14.61 - $15.33

52-Week Range

$10.27 - $18.67

Estimated Earnings Date

Jul 31, 2026

OPHLF News

Dividends blackboard sketch doodle

How to Invest in Schwab International Dividend Equity ETF (SCHY)

Tony DongFeb 27, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Industry

Pharmaceuticals

Sector

Health Care

Employees

4,206

CEO

Gyo Sagara

Website

www.ono-pharma.com/ja

Headquarters

Osaka, OS 541-8564, JP

OPHLF Financials

Key Financial Metrics (TTM)

Gross Margin

72.52%

Operating Margin

20.03%

Net Income Margin

13.53%

Return on Equity

8.54%

Return on Capital

10.63%

Return on Assets

6.31%

Earnings Yield

6.80%

Dividend Yield

3.57%

Payout Ratio

53.80%

Stock Overview

Market Cap

$6.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

469.91M

Volume

1.01K

Avg. Volume

128.307

Financials (TTM)

Gross Profit

¥376.05B

Operating Income

¥102.68B

EBITDA

¥141.27B

Operating Cash Flow

¥137.90B

Capital Expenditure

-¥6.06B

Free Cash Flow

¥131.84B

Cash & ST Invst.

¥238.60B

Total Debt

¥120.94B

Ono Pharmaceutical Performance Analysis

Ono Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 3,301,177,9722.7%
20242024-03-31JPY 3,480,784,4685.4%
20252025-03-31JPY 3,193,636,134-8.2%
20262026-03-31JPY 3,422,774,3307.2%
Ono Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3013.6%
Q22025-09-303.1%
Q32025-12-316.5%
Q42026-03-31-14.7%
Ono Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.7018.1%
20242024-03-31JPY 1.858.3%
20252025-03-31JPY 0.70-62.2%
20262026-03-31JPY 0.9841.1%
Ono Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30370.4%
Q22025-09-3028.8%
Q32025-12-3127.0%
Q42026-03-31-97.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

¥119.50B

+6.4%

Gross Profit

¥86.23B

+28.6%

Gross Margin

72.16%

N/A

Market Cap

$6.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.63M

N/A

Employees

4,206

N/A

Net Income

¥823.15M

+112.6%

EBITDA

¥22.16B

+482.8%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

¥238.60B

+13.4%

Total Debt

¥120.94B

-17.6%

Accounts Receivable

¥146.85B

+8.8%

Inventory

¥57.81B

-22.8%

Long Term Debt

¥82.99B

-26.9%

Short Term Debt

¥38.47B

+15.9%

Return on Assets

6.31%

N/A

Return on Invested Capital

10.96%

N/A

Free Cash Flow

¥49.42B

+31.5%

Operating Cash Flow

¥50.50B

+29.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
KYKOFKyowa Kirin Co., Ltd.
$14.43+0.00%
HKMPYHikma Pharmaceuticals PLC
$41.27+0.00%
HKMPFHikma Pharmaceuticals PLC
$20.37+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About OPHLF

What is the current price of Ono Pharmaceutical?

Ono Pharmaceutical is trading at $14.61 per share.

What is the 52-week range for Ono Pharmaceutical?

Over the past 52 weeks, Ono Pharmaceutical has traded between $10.27 and $18.67.

How much debt does Ono Pharmaceutical have?

As of the most recent reporting period, Ono Pharmaceutical reported total debt of ¥760.17M.

How much cash does Ono Pharmaceutical have on hand?

Ono Pharmaceutical reported ¥1.49B in cash and cash equivalents in its most recent financial results.

What is Ono Pharmaceutical’s dividend yield?

Ono Pharmaceutical currently has a dividend yield of 3.57%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services